Signals, Powered By EquityPandit
Zydus Cadila has got the final approval from the US health regulator for marketing blood pressure drug, Tiadylt ER.
Cadila Healthcare has said in a BSE filing that the approval by the US Food and Drug Administration (USFDA) for diltiazem hydrochloride (Tiadylt ER) extended release capsules is for multiple strengths of 120mg, 180mg, 240mg, 300mg and 420mg.
It added that “The drug will be manufactured at the group’s formulations manufacturing facility at pharma SEZ in Ahmedabad.”
